Xilio Therapeutics Files Q1 2025 10-Q
Ticker: XLO · Form: 10-Q · Filed: May 8, 2025 · CIK: 1840233
Sentiment: neutral
Topics: 10-Q, biotech, clinical-stage, oncology
Related Tickers: XLO
TL;DR
Xilio Tx 10-Q filed. Q1 2025 update. Still in immuno-oncology play.
AI Summary
Xilio Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company's primary focus remains on its clinical-stage immuno-oncology programs. During the quarter, Xilio continued its operations and filed necessary disclosures, including information related to its stock incentive plans and sales agreements with entities like Leerink and Cowen.
Why It Matters
This filing provides an update on Xilio Therapeutics' financial and operational status for the first quarter of 2025, crucial for investors tracking the company's progress in the competitive immuno-oncology space.
Risk Assessment
Risk Level: medium — As a clinical-stage biotechnology company, Xilio Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the fiscal quarter for this 10-Q filing.)
- 20250508 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- 20250331 (date) — Conformed period of report
- 0001840233 (company) — Central Index Key for Xilio Therapeutics, Inc.
- Leerink (company) — Mentioned in relation to a sales agreement
- Cowen (company) — Mentioned in relation to a sales agreement
- F. Hoffmann-La Roche Ltd (company) — Party to a Clinical Supply Agreement
FAQ
What is the primary business of Xilio Therapeutics, Inc. as indicated in this filing?
Xilio Therapeutics, Inc. is focused on clinical-stage immuno-oncology programs.
What is the reporting period for this 10-Q filing?
The conformed period of report is March 31, 2025.
Which sales agreements are mentioned in relation to Xilio Therapeutics?
Sales agreements with Leerink and Cowen are mentioned, with dates ranging from March 2025 and November 2022 respectively.
Does Xilio Therapeutics have any agreements with F. Hoffmann-La Roche Ltd?
Yes, Xilio Therapeutics has a Clinical Supply Agreement with F. Hoffmann-La Roche Ltd, with activity noted in Q1 2025 and Q1 2024.
When was Xilio Therapeutics, Inc. incorporated?
The company was incorporated in Delaware (DE).
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Xilio Therapeutics, Inc. (XLO).